top of page

Institute for Translational Vaccinology (ITV)

Intravacc is a renowned, not-for-profit translational R&D organization with 100+ years of experience in vaccine development. We offer a wide range of solutions for optimizing vaccines, vaccine processes, and vaccine technologies. Our broad technological capabilities can guide your innovative vaccine concept through the development chain, bridging the gap between early discovery and late stage clinical studies. We share and transfer our knowledge and technologies to partners worldwide, providing opportunities for contract research and out-licensing of (in-house) developed vaccine technologies.

Role in the TRANSVAC project

ITV will provide access to its panel of neisserial LPS-derived adjuvant candidates. The service will include formulation, stability testing, physicochemical characterization of adjuvants and vaccines, and ex vivo innate response evaluation on cell lines or human antigen-presenting cells.

Main staff involved in TRANSVAC

Dr. Peter van der Ley;

The Facility

Detoxified LPS immunomodulatory adjuvants are the most common PAMP compounds, but only one variant (from Salmonella) is currently included in a registered adjuvant product. Neisseria meningitidis contains a very potent hexa-acylated LPS that would be too toxic for therapeutic applications. We have used systematic molecular bioengineering of the meningococcal LPS through deletion of enzymes involved in LPS biosynthesis in combination with induction of LPS modifying enzymes (for example the deacylase PagL) to yield a variety of novel LPS mutant strains with changes in both lipid A acylation and phosphorylation. Altogether these purified LPS derivatives display a broad range of TLR4 activity and differential cytokine inducing properties, which can be exploited for use as an adjuvant in vaccines We will use our panel of genetically-detoxified LPS compounds to optimise their preferred presentation form and delivery vehicle. Their physicochemical states will be assessed, including aggregation behaviour and dynamics, and abilities to influence in vitro innate immune responses (antigen presenting cell (APC) activation, cytokine induction) quantified. The purified LPS will then be formulated in well-characterised particles, e.g. liposomes. The design space will be determined using parameters such as lipid composition, particle size, and LPS loading.

TNA or Training provided

Intravacc has several detoxified LPS variants available for testing with your antigen of choice. The LPS adjuvant platform technology of Intravacc is open for new collaborations, which can range from out-licensing to large collaborative development, process optimization and cGMP production.






bottom of page